Gemtuzumab Oz Ozogamicin represents a significant advance in the treatment of aggressive myeloblastic cancer, particularly relapsed myeloid leukemia (AML). This agent joins a humanized immunoglobulin directed for the https://www.targetmol.com/compound/gemtuzumab